Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018, Article ID 7357162, 18 pages
https://doi.org/10.1155/2018/7357162
Research Article

Cathelicidin LL-37 Affects Surface and Intracellular Toll-Like Receptor Expression in Tissue Mast Cells

1Department of Experimental Immunology, Faculty of Health Sciences, Medical University of Lodz, Lodz, Poland
2Department of Molecular Cell Mechanisms, Faculty of Health Sciences, Medical University of Lodz, Lodz, Poland
3Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Faculty of Pharmacy, Medical University of Lodz, Lodz, Poland
4Department of Industrial Microbiology and Biotechnology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland

Correspondence should be addressed to Ewa Brzezińska-Błaszczyk; lp.zdol.demu.ksc@bawe

Received 1 September 2017; Accepted 26 November 2017; Published 19 February 2018

Academic Editor: Xiao-Feng Yang

Copyright © 2018 Justyna Agier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K.-Y. Choi, L. N. Y. Chow, and N. Mookherjee, “Cationic host defence peptides: multifaceted role in immune modulation and inflammation,” Journal of Innate Immunity, vol. 4, no. 4, pp. 361–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. C. Mansour, O. M. Pena, and R. E. W. Hancock, “Host defense peptides: front-line immunomodulators,” Trends in Immunology, vol. 35, no. 9, pp. 443–450, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Vandamme, B. Landuyt, W. Luyten, and L. Schoofs, “A comprehensive summary of LL-37, the factotum human cathelicidin peptide,” Cellular Immunology, vol. 280, no. 1, pp. 22–35, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Bocchinfuso, A. Palleschi, B. Orioni et al., “Different mechanisms of action of antimicrobial peptides: insights from fluorescence spectroscopy experiments and molecular dynamics simulations,” Journal of Peptide Science, vol. 15, no. 9, pp. 550–558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Scott, S. Weldon, P. J. Buchanan et al., “Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo,” PLoS One, vol. 6, no. 10, article e26525, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. S. Jacobsen and H. Jenssen, “Human cathelicidin LL-37 prevents bacterial biofilm formation,” Future Medicinal Chemistry, vol. 4, no. 12, pp. 1587–1599, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Agier, M. Efenberger, and E. Brzezińska-Błaszczyk, “Cathelicidin impact on inflammatory cells,” Central European Journal of Immunology, vol. 40, no. 2, pp. 225–235, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Yang, Q. Chen, A. P. Schmidt et al., “LL-37, the neutrophil granule–and epithelial cell–derived cathelicidin, utilizes formyl peptide receptor–like 1 (Fprl1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells,” The Journal of Experimental Medicine, vol. 192, no. 7, pp. 1069–1074, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. G. S. Tjabringa, D. K. Ninaber, J. W. Drijfhout, K. F. Rabe, and P. S. Hiemstra, “Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors,” International Archives of Allergy and Immunology, vol. 140, no. 2, pp. 103–112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Bąbolewska and E. Brzezińska-Błaszczyk, “Human-derived cathelicidin LL-37 directly activates mast cells to proinflammatory mediator synthesis and migratory response,” Cellular Immunology, vol. 293, no. 2, pp. 67–73, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. G. Scott, D. J. Davidson, M. R. Gold, D. Bowdish, and R. E. W. Hancock, “The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses,” The Journal of Immunology, vol. 169, no. 7, pp. 3883–3891, 2002. View at Publisher · View at Google Scholar
  12. N. Mookherjee, P. Hamill, J. Gardy et al., “Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells,” Molecular BioSystems, vol. 5, no. 5, pp. 483–496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. G. Barlow, Y. Li, T. S. Wilkinson et al., “The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system,” Journal of Leukocyte Biology, vol. 80, no. 3, pp. 509–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Nagaoka, H. Tamura, and M. Hirata, “An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7,” The Journal of Immunology, vol. 176, no. 5, pp. 3044–3052, 2006. View at Publisher · View at Google Scholar
  15. A. Neumann, E. T. M. Berends, A. Nerlich et al., “The antimicrobial peptide LL-37 facilitates the formation of neutrophil extracellular traps,” Biochemical Journal, vol. 464, no. 1, pp. 3–11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Yuk, D. M. Shin, H. M. Lee et al., “Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin,” Cell Host & Microbe, vol. 6, no. 3, pp. 231–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. N. Rao and M. A. Brown, “Mast cells: multifaceted immune cells with diverse roles in health and disease,” Annals of the New York Academy of Sciences, vol. 1143, no. 1, pp. 83–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. H. R. Rodewald and T. B. Feyerabend, “Widespread immunological functions of mast cells: fact or fiction?” Immunity, vol. 37, no. 1, pp. 13–24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Di Nardo, A. Vitiello, and R. L. Gallo, “Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide,” The Journal of Immunology, vol. 170, no. 5, pp. 2274–2278, 2003. View at Publisher · View at Google Scholar
  20. M. Arock, E. Ross, R. Lai-Kuen, G. Averlant, Z. Gao, and S. N. Abraham, “Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria,” Infection and Immunity, vol. 66, no. 12, pp. 6030–6034, 1998. View at Google Scholar
  21. H. G. Lima, K. H. Pinke, T. P. Gardizani et al., “Mast cells act as phagocytes against the periodontopathogen Aggregatibacter actinomycetemcomitans,” Journal of Periodontology, vol. 84, no. 2, pp. 265–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Malaviya, N. J. Twesten, E. A. Ross, S. N. Abraham, and J. D. Pfeifer, “Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells,” The Journal of Immunology, vol. 156, no. 4, pp. 1490–1496, 1996. View at Google Scholar
  23. P. Frandji, C. Oskéritzian, F. Cacaraci et al., “Antigen-dependent stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma,” The Journal of Immunology, vol. 151, no. 11, pp. 6318–6328, 1993. View at Google Scholar
  24. M. Urb and D. C. Sheppard, “The role of mast cells in the defence against pathogens,” PLoS Pathogens, vol. 8, no. 4, article e1002619, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Sandig and S. Bulfone-Paus, “TLR signaling in mast cells: common and unique features,” Frontiers in Immunology, vol. 3, p. 185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Saluja, M. Metz, and M. Maurer, “Role and relevance of mast cells in fungal infections,” Frontiers in Immunology, vol. 3, p. 146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Fukuda, H. Ushio, J. Kawasaki et al., “Expression and functional characterization of retinoic acid-inducible gene-I-like receptors of mast cells in response to viral infection,” Journal of Innate Immunity, vol. 5, no. 2, pp. 163–173, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Bąbolewska, A. Pietrzak, and E. Brzezińska-Błaszczyk, “Cathelicidin rCRAMP stimulates rat mast cells to generate cysteinyl leukotrienes, synthesize TNF and migrate: involvement of PLC/A2, PI3K and MAPK signaling pathways,” International Immunology, vol. 26, no. 11, pp. 637–646, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Agier, P. Żelechowska, E. Kozłowska, and E. Brzezińska-Błaszczyk, “Expression of surface and intracellular Toll-like receptors by mature mast cells,” Central European Journal of Immunology, vol. 41, no. 4, pp. 333–338, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Agier, S. Różalska, K. Wódz, and E. Brzezińska-Błaszczyk, “Leukotriene receptor expression in mast cells is affected by their agonists,” Cellular Immunology, vol. 317, pp. 37–47, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Brzezińska-Błaszczyk and M. Wierzbicki, “Mast cell Toll-like receptors (TLRs),” Postepy Higieny Medycyny Doswiadczalnej, vol. 64, pp. 11–21, 2010. View at Google Scholar
  32. T. Matsuguchi, T. Musikacharoen, T. Ogawa, and Y. Yoshikai, “Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages,” The Journal of Immunology, vol. 165, no. 10, pp. 5767–5772, 2000. View at Publisher · View at Google Scholar
  33. E. A. Kurt-Jones, L. Mandell, C. Whitney et al., “Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils,” Blood, vol. 100, no. 5, pp. 1860–1868, 2002. View at Google Scholar
  34. Y. Mita, K. Dobashi, Y. Shimizu, T. Nakazawa, and M. Mori, “Toll-like receptor 2 and 4 surface expressions on human monocytes are modulated by interferon-γ and macrophage colony-stimulating factor,” Immunology Letters, vol. 78, no. 2, pp. 97–101, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Okumura, J. Kashiwakura, H. Tomita et al., “Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcϵRI,” Blood, vol. 102, no. 7, pp. 2547–2554, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Yang, J. Wei, H. Zhang et al., “Upregulation of Toll-like receptor (TLR) expression and release of cytokines from mast cells by IL-12,” Cellular Physiology and Biochemistry, vol. 26, no. 3, pp. 337–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Pietrzak, M. Wierzbicki, M. Wiktorska, and E. Brzezińska-Błaszczyk, “Surface TLR2 and TLR4 expression on mature rat mast cells can be affected by some bacterial components and proinflammatory cytokines,” Mediators of Inflammation, vol. 2011, Article ID 427473, 11 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Yang, J. Wei, H. Zhang, L. Lin, W. Zhang, and S. He, “Upregulation of Toll-like receptor (TLR) expression and release of cytokines from P815 mast cells by GM-CSF,” BMC Cell Biology, vol. 10, no. 1, p. 37, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Yoshioka, N. Fukuishi, Y. Kubo et al., “Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity,” Biological and Pharmaceutical Bulletin, vol. 31, no. 2, pp. 212–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Subramanian, K. Gupta, Q. Guo, R. Price, and H. Ali, “Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to receptor phosphorylation, desensitization, and internalization,” The Journal of Biological Chemistry, vol. 286, no. 52, pp. 44739–44749, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. X. Chen, F. Niyonsaba, H. Ushio et al., “Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells,” Journal of Dermatological Science, vol. 43, no. 1, pp. 63–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Schiemann, E. Brandt, R. Gross et al., “The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4,” The Journal of Immunology, vol. 183, no. 4, pp. 2223–2231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Niyonsaba, A. Someya, M. Hirata, H. Ogawa, and I. Nagaoka, “Evaluation of the effects of peptide antibiotics human β-defensins-1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells,” European Journal of Immunology, vol. 31, no. 4, pp. 1066–1075, 2001. View at Publisher · View at Google Scholar
  44. F. Niyonsaba, H. Ushio, M. Hara et al., “Antimicrobial peptides human β-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells,” The Journal of Immunology, vol. 184, no. 7, pp. 3526–3534, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Xiao, Y. P. Hsu, A. Ishizaka, T. Kirikae, and R. B. Moss, “Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation,” Chest, vol. 128, no. 4, pp. 2316–2326, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. T. D. Starner, B. Agerberth, G. H. Gudmundsson, and P. B. McCray Jr., “Expression and activity of β-defensins and LL-37 in the developing human lung,” The Journal of Immunology, vol. 174, no. 3, pp. 1608–1615, 2005. View at Publisher · View at Google Scholar
  47. S. Davidopoulou, E. Diza, D. Sakellari, G. Menexes, and S. Kalfas, “Salivary concentration of free LL-37 in edentulism, chronic periodontitis and healthy periodontium,” Archives of Oral Biology, vol. 58, no. 8, pp. 930–934, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Mandic Havelka, E. Yektaei-Karin, K. Hultenby et al., “Maternal plasma level of antimicrobial peptide LL37 is a major determinant factor of neonatal plasma LL37 level,” Acta Paediatrica, vol. 99, no. 6, pp. 836–841, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. O. Sørensen, J. B. Cowland, J. Askaa, and N. Borregaard, “An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma,” Journal of Immunological Methods, vol. 206, no. 1-2, pp. 53–59, 1997. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Kozłowska, A. Wysokiński, and E. Brzezińska-Błaszczyk, “Serum levels of peptide cathelicidin LL-37 in elderly patients with depression,” Psychiatry Research, vol. 255, pp. 156–160, 2017. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Majewski, P. Żelechowska, and E. Brzezińska-Błaszczyk, “Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases,” Clinical and Investigative Medicine, vol. 40, no. 1, pp. E34–E39, 2017. View at Publisher · View at Google Scholar
  52. L. Jeng, A. V. Yamshchikov, S. E. Judd et al., “Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis,” Journal of Translational Medicine, vol. 7, no. 1, p. 28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Murakami, T. Ohtake, R. A. Dorschner, R. L. Gallo, B. Schittek, and C. Garbe, “Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin,” Journal of Investigative Dermatology, vol. 119, no. 5, pp. 1090–1095, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Schaller-Bals, A. Schulze, and R. Bals, “Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 7, pp. 992–995, 2002. View at Publisher · View at Google Scholar
  55. S. Wantha, J.-E. Alard, R. T. A. Megens et al., “Neutrophil-derived cathelicidin promotes adhesion of classical monocytes,” Circulation Research, vol. 112, no. 5, pp. 792–801, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Sun, B. Dahlén, B. Agerberth, and J. Z. Haeggström, “The antimicrobial peptide LL-37 induces synthesis and release of cysteinyl leukotrienes from human eosinophils – implications for asthma,” Allergy, vol. 68, no. 3, pp. 304–311, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. G. S. Tjabringa, J. Aarbiou, D. K. Ninaber et al., “The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor,” The Journal of Immunology, vol. 171, no. 12, pp. 6690–6696, 2003. View at Publisher · View at Google Scholar
  58. R. Shaykhiev, C. Beißwenger, K. Kändler et al., “Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 289, no. 5, pp. L842–L848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Tokumaru, K. Sayama, Y. Shirakata et al., “Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37,” The Journal of Immunology, vol. 175, no. 7, pp. 4662–4668, 2005. View at Publisher · View at Google Scholar
  60. A. Elssner, M. Duncan, M. Gavrilin, and M. D. Wewers, “A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release,” The Journal of Immunology, vol. 172, no. 8, pp. 4987–4994, 2004. View at Publisher · View at Google Scholar
  61. P. Montreekachon, P. Chotjumlong, J. G. M. Bolscher, K. Nazmi, V. Reutrakul, and S. Krisanaprakornkit, “Involvement of P2X7 purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts,” Journal of Periodontal Research, vol. 46, no. 3, pp. 327–337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Wan, O. Soehnlein, X. Tang et al., “Cathelicidin LL-37 induces time-resolved release of LTB4 and TXA2 by human macrophages and triggers eicosanoid generation in vivo,” FASEB Journal, vol. 28, no. 8, pp. 3456–3467, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. Z. Zhang, G. Cherryholmes, F. Chang, D. M. Rose, I. Schraufstatter, and J. E. Shively, “Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils,” European Journal of Immunology, vol. 39, no. 11, pp. 3181–3194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Niyonsaba, K. Iwabuchi, A. Someya et al., “A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis,” Immunology, vol. 106, no. 1, pp. 20–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Yu, Y. Zhang, Y. Zhang et al., “LL-37-induced human mast cell activation through G protein-coupled receptor MrgX2,” International Immunopharmacology, vol. 49, pp. 6–12, 2017. View at Publisher · View at Google Scholar · View at Scopus